...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Case Reports in Pediatrics >Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma
【24h】

Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma

机译：早期使用Dinutuximabβ患者高危神经母细胞瘤

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Neuroblastoma is the most common extracranial solid tumor in children, accounting for 15% of all pediatric cancer deaths. High-risk neuroblastoma (HRNB) is a particularly difficult-to-treat form of the disease that requires aggressive multimodality therapy, including induction chemotherapy, consolidation therapy with high-dose chemotherapy and autologous stem cell transplant, and maintenance therapy with dinutuximab beta. Despite treatment advances, the prognosis of these patients remains poor. As a better response to induction therapy has been associated with prolonged survival in patients with HRNB, we hypothesized that early use of dinutuximab beta—post-induction chemotherapy—may improve patient outcomes. We describe here our experience of administering at least one cycle of dinutuximab beta post-induction and prior to surgery in three children with HRNB who did not demonstrate a complete response to induction chemotherapy. All three patients achieved complete remission. Early use of dinutuximab beta may therefore have the potential to improve outcomes in patients with HRNB.
机译：神经母细胞瘤是儿童中最常见的颅外实体肿瘤，占所有儿科癌症死亡的15％。高风险的神经母细胞瘤（HRNB）是一种特别难以治疗的疾病形式，需要侵袭性多重疗法，包括诱导化疗，与高剂量化疗和自体干细胞移植的固结治疗，以及与DINOUXIMABβ的维持治疗。尽管治疗进展，但这些患者的预后仍然差。作为对诱导治疗的更好反应，HRNB患者的延长存活率有关，我们假设早期使用Dinutuximabβ-后诱导化疗 - 可以改善患者结果。我们在这里描述了我们在诱导后诱导的至少一个循环诱导的内容和HRNB的三个孩子手术前的经验，并没有表现出对诱导化疗的完全反应。所有三名患者都取得了完全缓解。因此，Dinutuximabβ的早期使用可能有可能改善HRNB患者的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号